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Aim: To understand stakeholders’ views on data sharing in multicenter comparative 
effectiveness research studies and the value of privacy-protecting methods. Materials 
& methods: Semistructured interviews with five US stakeholder groups. Results: We 
completed 11 interviews, involving patients (n = 15), researchers (n = 10), Institutional 
Review Board and regulatory staff (n = 3), multicenter research governance experts 
(n = 2) and healthcare system leaders (n = 4). Perceptions of the benefits and value of 
research were the strongest influences toward data sharing; cost and security risks were 
primary influences against sharing. Privacy-protecting methods that share summary-
level data were acknowledged as being appealing, but there were concerns about 
increased cost and potential loss of research validity. Conclusion: Stakeholders were 
open to data sharing in multicenter studies that offer value and minimize security risks.
First draft submitted: 7 February 2017; Accepted for publication: 25 April 2017; 
Published online: 14 August 2017
Keywords:  comparative effectiveness research • data sharing • distributed research networks 
• electronic databases • multicenter studies • PCORnet • privacy-protecting methods
Multicenter research networks support a 
wide range of patient-centered outcomes 
research, comparative effectiveness and 
safety research, and public health surveil-
lance activities [1,2]. They allow stakeholders 
to generate timely and actionable informa-
tion, study treatment effect heterogeneity 
in large and diverse populations, and pro-
duce generalizable results. In the past, it 
has often been necessary to share highly 
granular and potentially identifiable patient-
level information across healthcare systems 
to perform the desired statistical analysis. 
Even when organizations are willing to col-
laborate and share information, they must 
address issues surrounding patient privacy 
and confidentiality, data security, data con-
trol and proprietary interest to meet federal, 
state and institutional requirements. Meet-
ing these requirements can result in real or 
perceived loss of efficiency associated with 
extensive, time-consuming negotiations 
and the administrative paperwork burden 
(e.g., Institutional Review Board [IRB] 
approvals, data use agreements).
The advent of several new analytic and 
data-sharing methods offers a more efficient 
way of tackling these requirements [3–9]. 
For certain analyses, these methods require 
only summary-level data, such as propensity 
scores or intermediate statistics from regres-
sion models, to produce results identical or 
highly comparable to those from pooled 
patient-level data analysis [3–9]. These newer 
methods are considered more ‘privacy-pro-
tecting’ as they do not require exchange of 
potentially identifiable information. They 
have the potential to improve the efficiency 
of research through more streamlined secu-
rity and privacy protection requirements, and 
could enhance stakeholders’ willingness and 
ability to collaborate in multicenter studies.
Existing research suggests that patients 
and the public are concerned about the 
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privacy of their electronic health information, but 
also value research that has the potential to improve 
care [10–12]. At the same time, most patients and mem-
bers of the public are not familiar with how their data 
may be shared, and how their privacy is currently pro-
tected [10,13,14]. The new privacy-protecting methods 
are especially unfamiliar to the public, and relatively 
unfamiliar to most stakeholders involved in research. 
These methods may also lack the capability to address 
some stakeholders’ needs and preferences. Regardless 
of how robust or secure, methods are of limited value 
if not known to, understood by and proven to be use-
ful to stakeholders. The goal of this qualitative study 
was to explore and describe various stakeholders’ 
views on sharing of electronic health information in 
multicenter comparative effectiveness research studies 
and on privacy-protecting methods in particular.
Materials & methods 
Stakeholder groups interviewed
For the purposes of this study, we defined our 
stakeholders as individuals contributing data to mul-
ticenter studies, individuals responsible for steward-
ship of patient data and the requirements associated 
with engaging their institutions in data sharing, 
individuals involved in overseeing and conducting 
multicenter studies, or individuals involved in using 
the results of multicenter studies [15]. We identified 
and invited a purposive sample of stakeholders to par-
ticipate in the study, including patients, healthcare 
system leaders, experts in the governance of multi-
center studies, researchers and experts who review or 
oversee compliance, confidentiality and regulatory 
requirements of research studies.
We recruited patients from two existing groups: 
a bariatric surgery patient advisory panel previously 
convened to advise on a research application and 
patients who participated in the Arthritis Partnership 
with Comparative Effectiveness Research (known 
as ArthritisPower™; Upper Nyack, NY, USA), 
a Patient-Powered Research Network within the 
National Patient-Centered Clinical Research Net-
work (PCORnet) [16]. We chose these two existing 
groups because this study was conducted in the con-
text of a larger project that involves patients who have 
undergone or are considering bariatric procedures 
and patients with autoimmune diseases. We identified 
healthcare systems leaders, experts in the governance 
of multicenter studies and experts in research com-
pliance, confidentiality and regulatory requirements 
from three delivery systems: Group Health Research 
Institute (now Kaiser Permanente Washington 
Health Research Institute), Kaiser Permanente Colo-
rado and Kaiser Permanente Northern California. We 
enrolled researchers from the attendees of the Patient-
Centered Outcomes Research Institute (PCORI) 
Annual Meeting in 2015. In the following text, we 
refer to patient stakeholders as ‘patients’ and to all 
other participants as ‘organizational stakeholders’.
Data-sharing & analytic methods of interest
We were interested in stakeholders’ views on various 
data-sharing and analytic methods used in multicenter 
studies, including pooled patient-level data analy-
sis, patient-level or summary-level data analysis that 
leverage confounder summary scores (e.g., propensity 
scores), risk set-based analysis, and meta-analysis 
of site-specific effect estimates [3–6]. Each method 
requires sharing specific information across sites 
and offers various degrees of analytic flexibility. See 
Supplementary Appendix 1 for examples of information 
typically shared by a participating site in a multicenter 
study using these analytic methods. Detailed descrip-
tion of the strengths and limitations of each method is 
available in other published articles [3–6].
Interview process & content
Prior to each interview, we sent stakeholders a fact sheet 
that described the purpose of the study, potential risks of 
the interview (which were minimal) and their expected 
level of participation (see Supplementary Appendix 2 for 
a version shared with the healthcare system leaders). 
We conducted the interviews in person or via tele-
phone, as a group or individually, based on the prefer-
ence and availability of the stakeholders. One author 
(S Toh) conducted all interviews. At least one other 
member of the research team was also present for all 
interviews. Each interview began with a review and 
clarification of the fact sheet. The interviewer then 
described various data-sharing and analytic methods 
in multicenter studies using educational materials (see 
Supplementary Appendix 3 for a version used for the 
interviews with the healthcare system leaders) tailored 
to the background of the interviewees. The presenta-
tions and interviews focused on data typically captured 
in electronic health records and administrative claims 
databases, rather than biospecimens or genetic data. 
The interviewer then asked the interviewees a series of 
questions based on the domains developed by the study 
team (Box 1). The specific interview questions varied 
depending on the interviewee’s role and familiarity 
with data sharing, and evolved over the course of the 
interview (see Supplementary Appendix 4 for an inter-
view guide used for the healthcare system leaders). We 
recorded all interviews with permission from the inter-
viewees and professionally transcribed them for anal-
ysis. We did not collect any identifiable information 
about the interviewees during the interview.
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Analysis
We used an integrated approach to the qualitative 
data analysis as described by Bradley et al. [17]. The 
interview domains provided an initial organizing 
framework, consistent with a directed content analy-
sis approach [18]. However, we were attentive to unan-
ticipated content as we reviewed the transcripts and 
applied the evolving coding scheme, integrating new 
codes and concepts as they emerged inductively, con-
sistent with conventional content analysis [18]. One 
investigator (KM Mazor) created an initial coding 
framework after observing four interviews. Two other 
investigators (S Toh, DE Arterburn), who had par-
ticipated in the interviews provided feedback on the 
framework, and suggested additional themes or sub-
themes. The first investigator (KM Mazor) elaborated 
the framework through ongoing review of the tran-
scripts as additional interviews were completed. Four 
team members (S Toh, DE Arterburn, MA Raebel and 
A Richards) each reviewed at least one transcript, with 
the coding framework at hand. These second readers 
checked for the completeness of the framework, and 
suggested new codes or modifications based on their 
review. The full qualitative team (KM Mazor, S Toh, 
DE Arterburn, MA Raebel and A Richards) reviewed 
and reached consensus that the final coding framework 
captured all relevant themes and subthemes expressed 
in the interviews (Supplementary Appendix 5). One 
team member (A Richards) coded all transcripts; 
a second team member (KM Mazor) reviewed the 
coded transcripts to confirm accuracy, and to resolve 
any questions that emerged during the final cod-
ing. The team entered the transcripts and codes into 
the Statistical Package for the Social Sciences (SPSS 
version 22) in order to facilitate data management, 
manipulation and reporting.
Results
We interviewed 34 stakeholders between June 2015 and 
February 2016 (Table 1). The average interview dura-
tion was approximately 61 min (range: 36–109 min). 
The analysis identified three major themes which 
emerged inductively from the qualitative analysis: per-
ceived benefits and value of research, cost and perceived 
risks. Figure 1 provides a conceptual model of how 
these major themes relate to stakeholders’ willingness 
Box 1. Interview domains.
•	 Familiarity and experience with multicenter research and data sharing
•	 Attitudes toward multicenter research and data sharing
•	 Perspectives on privacy and data security
•	 Perspectives on sharing aggregate-level versus individual-level data
•	 Recommendations for improving processes around data sharing
•	 Reactions to privacy-protecting analytic and data-sharing approaches
Note: Specific interview questions varied across interviews depending on stakeholders’ roles and responses.
Table 1. Stakeholder groups interviewed.
Stakeholder group n Interview type Interview mode
Patients
Arthritis patient panel 10 Group In person
Bariatric patient panel 1 4 Group In person
Bariatric patient panel 2 1 Individual Telephone
Healthcare systems leaders
Vice president for governmental external relations 1 Individual Telephone
Executive medical director 1 Individual Telephone
Medical director for quality 1 Individual In person
Consultant for research compliance and ethics 1 Individual In person
Multicenter research governance experts
– Multicenter research governance expert 1 1 Individual In person
– Multicenter research governance expert 2 1 Individual In person
Researchers 10 Group In person
Compliance, confidentiality and regulatory experts 3 Group Telephone
Each row of this table represents a separate interview session, either group or individual.
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Figure 1. Major themes identified from the stakeholder interviews.
Safeguards
Experience
Relationship
Research
question
Analytic approach
Granularity of
information shared
Trust
Cost
Perceived benefits 
and value of research
Perceived risks
Willingness to share data
future science group
Research Article    Mazor, Richards, Gallagher et al.
to share data in multicenter studies, which was a cen-
tral focus on this study. Each of these major themes 
(perceived benefits and value, cost and perceived risks) 
was influenced by the granularity of the information 
to be shared, as well as by other factors (e.g., percep-
tions of risk were also influenced by past experiences). 
We noted varying levels of stakeholder familiarity with 
privacy-protecting analytic and data-sharing methods, 
as well as differences in views on the usefulness of these 
methods; these findings are presented last.
Factors that influenced willingness to share 
data in multicenter studies 
Perceived benefits & value of the research
Stakeholders’ perceptions of the purpose, benefit and 
value of the research were the strongest influences 
toward data sharing. Both patients and organiza-
tional stakeholders referred to the need for research 
that would answer questions that they perceived to 
be important, relevant and likely to improve care or 
outcomes for patients. They indicated they would 
be more likely to support data sharing in pursuit of 
those goals. As one patient said, “If it’s improving the 
general knowledge in service of people like me, that’s a 
good thing.” In contrast, patients were unwilling to 
share data if they perceived the request was motivated 
by financial gain or profit. Patients considered it 
both possible and highly objectionable that an entity 
might profit by selling their data.
Organizational stakeholders valued data sharing 
as a means of improving patient care, and of advanc-
ing understanding of treatment risks and side effects. 
They referred to the fact that multicenter data sharing 
necessarily results in larger datasets and thus enhances 
the ability to study rare diseases and rare outcomes 
(i.e., increased statistical power). Organizational 
stakeholders also referred to improving generaliz-
ability of study findings. As one organizational stake-
holder stated, “It seems like more data is better… more 
generalizable, more scientific.” Another noted that data 
sharing allows healthcare systems to “provide richer 
data to the world.”
Patients’ comments indicated a desire for their data 
to be helpful, and to lead to valid and actionable find-
ings with the potential to improve care for others. 
Patients referred to the need for “good science,” and rec-
ognized that not all studies achieve this. As one patient 
said, “I suppose it goes back to the risk/reward, … we’re 
getting good science out of these studies. And if we’re not, 
I think that’s a bigger problem than the privacy issue.”
Costs
Cost was a factor identified as influencing 
organizational stakeholders away from data sharing. 
Organizational stakeholders’ comments implied that 
financial consequences and costs of decisions were 
important in their decision-making, including their 
decision making related to their organization’s par-
ticipation in research and data sharing. These stake-
holders were cognizant of the costs associated with 
data sharing, and considered these when making 
decisions about data sharing. They noted that data 
sharing requires resources, most notably program-
mer or analyst time and expertise, which are often 
limited. As one organizational stakeholder noted 
“everything’s an opportunity cost.” None of the stake-
holders commented on how the costs of data sharing 
using privacy-protecting methods might be covered, 
though one organizational stakeholder commented 
that building on existing research networks, where 
the foundational work, such as the creation of shared 
data models, “ lowers the burden” of data sharing. This 
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stakeholder went on to say that in the short- to near-
term the additional costs associated with developing 
and implementing privacy-protecting methods would 
be “an investment in methods development,” but also 
noted that if a project did not fully cover the costs of 
participation, then “we can’t do it.”
While patients did not refer to the cost of data 
sharing per se, some mentioned compensation, believ-
ing that they should be compensated for the use of 
their data, with compensation being broadly defined 
to include financial compensation, expressions of 
appreciation and recognition and sharing of results. 
Patients also expressed concern that their data might 
be used for commercial purposes.
Perceived risks
Perceived risk was also identified as influencing 
stakeholders away from data sharing. The most 
prominent concern identified by organizational 
and patient stakeholders was loss of control of the 
data, with the associated risk of unauthorized use 
or disclosure. Interviewees expressed concerns that 
sensitive health information, including information 
about patients’ diagnoses and treatments, might be 
divulged to those who should not have access, and 
ultimately result in harm to patients. While patients 
were concerned about loss of confidentiality and 
unauthorized release of their information, few were 
explicit in identifying the downstream consequences 
of disclosure they were most worried about. One 
patient was somewhat specific, expressing a concern 
about the possible impact on employment, saying, 
“Twenty years ago, and you have HIV, you’re fired, … 
Today, not as much, but, like, I think that’s a factor.” 
Another patient referred to “my insurance company or 
somebody’s going to use that against me,” while another 
said simply “ it’s a stigma…it’s nobody’s business.”
Organizational stakeholders also alluded to the risk 
of data sharing resulting in damage to an organiza-
tion’s reputation, or loss of competitive advantage. 
One organizational stakeholder referred to using the 
litmus test “ if this were released and it ended up on the 
front page of the (newspaper name), what would that do? 
To our patients, to our reputation, et cetera.” Organiza-
tional stakeholders appeared concerned about the pos-
sibility that disclosed data could suggest that a given 
provider, clinic, or organization might be portrayed 
as a poor performer, referring to “ issues around qual-
ity outcomes, competition,” in this context. One orga-
nizational stakeholder referred to concerns about “a 
dataset and that gets in the wrong hands and you sud-
denly discover that, you know, this one clinic is horrible.” 
Another organizational stakeholder referred to the 
potentially competing interests of researchers within 
an organization, noting “you also have the researcher 
who might be trying to do, you know, kind of establish 
themselves in a particular topic area, and may feel some 
level of protectiveness over the data.” Overall, organi-
zational stakeholders were acutely aware that harm 
could result from a data breach or loss of patient con-
fidentiality secondary to data sharing, though none 
reported direct experience with such events. One 
organizational stakeholder referred to the widely pub-
licized data breach at the Veteran’s Health Adminis-
tration, saying “a data breach in VA research, as you 
may remember, completely shut down the VA research 
enterprise for a couple of years…It was horrible.”
It is noteworthy, however, that some patients and 
organizational stakeholders were not concerned about 
data sharing, and made explicit their belief that there 
was little risk of harm. One patient asked directly 
whether unauthorized disclosure was a problem with 
research data, saying “I guess I would want to know 
how rampant a problem it is,” later noting “The risk is 
much smaller than say, just me buying something with 
my credit card.”
Several factors influenced organizational and 
patient stakeholders’ perception of risk, as described 
in Figure 1.
Safeguards: Organizational stakeholders identified 
a number of safeguards and strategies used to mini-
mize risk of data breaches and to maximize data secu-
rity. Some organizational stakeholders indicated that 
such safeguards are currently in place; others indi-
cated that they would require that such safeguards 
be in place prior to data sharing. Approaches refer-
enced included technological approaches (e.g., use 
of encryption, firewalls), policies and contractual 
practices (e.g., data use agreements) and oversight for 
ensuring compliance with agreed upon practices.
Some organizational stakeholders noted their 
organizations required that an internal researcher 
be involved in all studies involving data sharing to 
reduce the risk of inappropriate use. Involvement of 
an internal researcher was also sometimes necessary 
to ensure that the nuances of the data were taken into 
account in analyses and reporting. Some organiza-
tional stakeholders were apparently acutely aware of 
the complexities of operational data, and the poten-
tial for naive users to make incorrect assumptions 
about the data which could, in turn, lead to erroneous 
and invalid results.
Organizational stakeholders also referred to 
restricting data access (again referring to the current 
implementation of such practices), and the need to 
obtain assurances about limits on access whenever 
data were shared. Patients also brought up the impor-
tance of restricting data access, oversight of such 
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restrictions and voiced specific questions about data 
security, for instance, wanting details on how the data 
would be transferred. Some patients expressed uncer-
tainty about current practices; as one patient said, “I 
don’t know who has access to my information.”
Prior experience: Stakeholders’ prior experience 
with data sharing influenced their views on the poten-
tial risks. Several organizational stakeholders referred 
to sharing data for research without problems or con-
cerns. Successful experiences appeared to reduce the 
perception of risk, at least for data sharing in similar 
contexts. No interviewees reported direct personal or 
organizational experience of negative consequences 
of data sharing, though one organizational stake-
holder referred to a “near miss,”  – for example, an 
event where identifiable data were almost shared, but 
were detected and prevented. Organizational stake-
holders also noted that if a data breach were to occur, 
it would be likely to have a major impact on the 
organization’s willingness to share data in the future.
Two patients mentioned personal experience 
working with data (one in a work setting, and one in 
an educational setting), and indicated that this expe-
rience had increased their comfort with data sharing. 
One patient noted “we would get datasets like this, 
and I mean, there was absolutely no way you could tell, 
you know, even what region the person was from … 
I can say as someone who has seen how it’s presented, 
you know, I feel safe.” Another patient also referred 
to being more comfortable when “everything’s just a 
number.” An organizational stakeholder also raised 
this issue, noting, “I don’t think the patients have a 
clear sense of when we go into a data warehouse and 
extract data, what that’s like, that they’re a string, with 
a random ID.”
Trust and relationships: both patients and 
organizational stakeholders referred to the need to 
trust the researchers or organization requesting data, 
both with respect to how the data would be used and 
in the users’ ability to ensure the data security. The 
degree of trust appeared to be influenced by familiar-
ity, and whether there was an existing relationship 
with the organization or individuals involved. As 
one patient stated “…with (organizations), you know, 
there’s years of trust there, and so forth. So that comes 
down to the people, knowing the people that are behind 
the scenes, working with that information.” Organi-
zational stakeholders were less willing to share with 
unfamiliar requestors. As one organizational stake-
holder stated: “ if we were approached by some other, 
new group we’ve never heard of, that our delivery sys-
tems or health insurers or whatever that we don’t know 
and they said, ‘Trust us, we would (laughs) have some 
trouble with that’.”
Type & granularity of data shared
The type of data to be shared and the degree of 
aggregation also influenced stakeholders’ views on the 
value, costs and risks of data sharing and their willing-
ness to share. In all multicenter studies, the research 
question drives the analytic approach which, in turn, 
dictates the type and granularity of information to be 
shared. Organizational stakeholders, especially those 
with oversight or regulatory responsibility, focused on 
whether the requested data elements were relevant to 
the research questions, and were unwilling to approve 
sharing of data elements that were not relevant. Orga-
nizational stakeholders were also reluctant to approve 
sharing of sensitive information such as HIV status, 
mental health status or alcohol use, and referred to 
requests for medical record numbers as ‘red flags’. 
Patients were generally unwilling to share names, 
birth dates, social security numbers and financial 
information; it was implicit in organizational stake-
holders’ comments that these would typically not be 
shared. Some patients wanted to specify as to which 
data elements would be shared, and the conditions 
under which these could be shared; others indicated 
they would want to be informed when their data were 
shared. In general, some research topics and data ele-
ments were considered more sensitive than others, 
and would receive greater scrutiny.
Both patients and organizational stakeholders 
made statements and asked questions about the rela-
tive advantages and disadvantages of summary- ver-
sus individual-level data. The risk reduction obtained 
by sharing summary-level data rather than individ-
ual-level data was attractive to some stakeholders. 
However, a repeated theme across several interviews 
was whether aggregating data resulted in a loss of 
information that would reduce the value or validity 
of the research. As one organizational stakeholder 
asked, “How much more generalizable knowledge can 
be obtained through – from the scientific perspective – 
in analyzing the patient-level data?” A patient asked 
a similar question, with a slightly different focus, 
saying, “Does this type of method, where you have less 
granular information, lead to a less actionable result?” 
and later “To me, actionability of research outweighs 
my privacy anxiety, significantly.” Some questioned 
whether summary-level data would allow as complete 
and nuanced exploration of the research question as 
individual-level data.
Organizational stakeholders expressed concerns 
about the costs involved, noting that creating summary-
level data files may require more technical and pro-
gramming expertise and additional resources to create. 
Devoting resources to aggregating data files was seen as 
having opportunity costs as well, as programmers and 
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analysts were viewed by some as a relatively scarce staff 
resource within their organization.
Some organizational stakeholders opined that sum-
mary-level-based approaches would be appropriate if 
the goal of the study was to answer a single, well-
defined research question, but that these approaches 
would be less useful if the goal was to gain a nuanced 
understanding of a phenomenon. As one organiza-
tional stakeholder put it, “…if you get something that’s 
surprising, you’ d want to know why and that means you 
have to unpack it … you probably can’t do that because 
some of those problems are in the way the propensity 
score was constructed.”
Some organizational stakeholders indicated that 
summary-level data approaches would not influence 
their willingness to share data. As one put it, “If I’m 
not comfortable giving you the individual stuff, I’m not 
going to be comfortable giving you the propensity score.” 
This leader went on to say, “It seems a trade-off and the 
question is, what do I gain for that trade-off and do I 
think that that was already at risk? If I saw the data as 
at risk, I don’t know that I’ d be wanting to participate.” 
However, individual-level data were not preferred by 
all organizational stakeholders: “Yes, you have more 
ability to do analysis on patient-level data, but it comes 
at a cost, right? Of security and privacy.” Another 
saw an advantage in planning and decision-making 
needed to assemble data for aggregate approaches, 
suggesting that specifying the variables to be included 
and the analysis prior to data sharing would result in a 
more ‘honest and transparent’ approach.
Familiarities with & views on the privacy-
protecting analytic & data-sharing methods
Patient stakeholders were unfamiliar with privacy-
protecting analytic and data-sharing methods; organi-
zational stakeholders expressed limited understanding. 
Most interviewees had never heard of one or more of 
these newer methods, but some researchers had used 
some of the methods (e.g., propensity score-based 
methods) in their studies.
Stakeholders’ reactions to the privacy-protecting 
analytic and data-sharing methods, as we described 
them during the interviews, were mixed. Some inter-
viewees did not perceive a need for these methods, and 
others did not view these methods as providing signif-
icantly greater privacy protection. Overall, organiza-
tional stakeholders considered current safeguards suf-
ficient. However, as one interviewee noted, if someone 
“made a big mistake” those views might change, result-
ing in a greater need for privacy-protecting methods. 
Some were uncertain of the relative advantages of the 
newer privacy-protecting methods (i.e., the approaches 
which were the ultimate focus of this investigation).
Other organizational stakeholders felt that use of 
privacy-protecting methods were clearly preferable 
to sharing patient-level data. As one organizational 
stakeholder said, “I believe that the cultural resistances 
to patient-level data sharing are so deeply embedded in 
organizations that the best approach is privacy-protecting 
methods … I think privacy-protecting methods allow us 
to patiently but persistently figure out better approaches 
to multi-site data.”
Some interviewees suggested that privacy-
protecting methods would be more acceptable to 
specific stakeholder groups. For instance, researchers 
predicted that IRBs would find these methods more 
acceptable. This was confirmed by a comment from 
an organizational stakeholder with IRB experience 
who said, “From an IRB perspective it’s great. It’s defi-
nitely better, there’s no question.” Another organiza-
tional stakeholder predicted “Our patients are going to 
be viscerally more comfortable with it.”
Patients’ comments were more equivocal. One 
patient, apparently unconvinced of the need for or 
value of privacy-protecting methods, commented 
“It’s a lot of trouble simply for me to feel a little more 
secure. And for my vote, it’s insignificantly more secure.” 
Another patient appeared not to perceive a need for 
privacy-protecting methods personally, but thought 
other patients might: “You know, there’s information 
I’m willing to give and information I’m not willing, you 
know, to – as long as you let me know. I don’t care. But 
I can see that there’s going to be a lot of people who aren’t 
so open, and I think this method would probably make 
them much more comfortable.”
Discussion of ways to increase the acceptance of 
privacy-protecting methods identified recommenda-
tions for providing additional evidence of the value 
of the approach. Some organizational stakeholders 
wanted to see examples of the application of these 
methods, and demonstrations of the equivalence of 
results obtained when using these methods compared 
with standard approaches. As one organizational 
stakeholder put it “…since these methods are opaque by 
design, I think the only way to overcome that is a series 
of studies that basically have access to both the full data-
set and the privacy protected methods and to show that 
across a wide array of questions, data structures, ana-
lytic techniques, that the results are identical.” Another 
stated “…we have to have confidence as a reader of the 
literature, that they (privacy-protecting methods) actu-
ally are correct.” A patient made a similar recommen-
dation, saying, “If you can say that you can get the same 
quality results from the summary, then I’ d go with that. 
But my – I question whether or not that’s true.”
The possibility that proposals using privacy-protecting 
methods might make it through the institutional review 
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process relatively quickly was noted as an advantage 
by some organizational stakeholders, and examples of 
instances where proposals using these methods resulted 
in more timely IRB approval would help to convince 
stakeholders of their value. Similarly, recognition of the 
resources needed to produce the summary-level datasets 
used in privacy-protecting analyses led to recommenda-
tions to find ways to make these methods cheaper, faster 
and more efficient.
One organizational leader referred to the ‘downside’ 
of privacy-protecting methods as “…the fact that all 
reputable researchers like to get the data under their fin-
gernails. You like to get dirty with the data. And when 
you can’t do that, then, then you get apprehensive and 
you should. That’s an instinct that was trained into all 
of us in graduate school. And so not being able to see the 
raw data makes us viscerally uncomfortable.”
Patients’ questions and comments also highlighted 
the need to inform and educate patients about cur-
rent practices and protections. As one patient stated 
“I think part of it comes down to, it’s just patients getting 
enough education about the process, and the outcomes 
that we’re looking for, to feel comfortable sharing that 
information, and to realize that you know what? Guess 
what? Maybe we, as a generation, need to go out on a 
limb a little bit here, but it’s that proper education of 
how this is going to be used, and proper thanks.”
Discussion
Multicenter research studies that leverage various 
existing data resources have the potential to generate 
timely, actionable and generalizable results. Our find-
ings from these interviews elucidate the factors that 
influence stakeholders’ views on data sharing in multi-
center research. Consistent with prior studies conducted 
in the USA, the UK, Canada and elsewhere [10–12,19,20], 
our findings suggest that while stakeholders generally 
recognize the value of research and are motivated to con-
tribute to better patient care and outcomes, many have 
reservations about data sharing for research. New ana-
lytic methods may reduce concerns about privacy and 
anonymity, but our findings suggest that other factors 
influence stakeholders’ views and must be considered.
Our findings extend what is known by providing 
insights into organizational stakeholders’ perspectives 
that were generally consistent with patients’ views, 
perhaps because most have responsibility for protect-
ing patient confidentiality and data security. While 
both patients and organizational stakeholders voiced 
questions and concerns, most were open to data shar-
ing as long as the research was addressing questions 
that were important to patient care.
A particular focus of these interviews was to explore 
stakeholders’ reactions to the newer privacy-protecting 
methods analytic and data-sharing methods. Our 
experience in these interviews highlights the fact that 
these methods were not well-understood by the stake-
holders. The methods were also difficult to explain, 
especially to less technical audiences. As we did 
explain them, reactions were mixed. While stakehold-
ers acknowledged that privacy-protecting methods 
enhanced privacy and reduced the risk of reidentifica-
tion of patients, these benefits were weighed against the 
cost of preparing the datasets, and the perception that 
such approaches might limit the value of the research 
by reducing generalizability, validity and the ability to 
explore nuances in the data. There are several ways to 
make multicenter studies more efficient, for example, 
by standardizing the databases in advance so that the 
analytic code can be developed by the study team and 
executed with minimal modifications at other partici-
pating sites [1,21–23]. Recent simulation and empirical 
studies have also shown that these methods produce 
results statistically equivalent to the results from 
pooled patient-level data analysis for certain study set-
tings [5,6,8,9]. The feedback from the stakeholders in 
this study highlights the need for better education and 
more research in these methods.
Trust emerged as an important influence in our 
interviews, for both patients and organizational stake-
holders. The importance of trust to patients has been 
reported previously [11,20,24–26]. Our finding that orga-
nizational stakeholders also consider trust and rela-
tionships when deciding about data sharing in the 
context of multicenter studies is not surprising. The 
stakeholder interviews provided insights into ways to 
build and maintain trust, including familiarity with 
the data requestor and proper safeguarding of the data.
The patients participating in this study were 
already engaged with the research process in some 
way and thus potentially more open to data sharing 
than other patients, but most did not convey a solid 
understanding of existing practices and safeguards 
around the use of their personal health information. 
All of the patient stakeholders in this study were 
familiar with research wherein individuals choose 
whether or not to participate, provide informed con-
sent and know generally what information they are 
providing to the researchers. However, many patients 
were not familiar with studies where electronic 
health data might be deidentified and shared with-
out documentation of patients’ permission. Patients 
with previous exposure to data analyses or reporting 
in the context of work or school appeared much less 
concerned about the risks associated with data shar-
ing. Typical patients without exposure to research 
or data analysis processes likely have an even more 
limited understanding of how data may be used and 
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what data sharing entails. This may influence their 
willingness to share their information for research. 
Our findings are consistent with prior studies that 
have documented patients are poorly informed as 
to current practices, safeguards and implications of 
data sharing [10–14,20,27,28].
Further, our findings highlight the need to 
improve patients’ awareness and understanding of 
the risks and benefits of research in general. Future 
studies are needed to identify the best methods of 
educating the public about existing safeguards and 
data sharing practices, as well as the need for, and 
potential value of, comparative effectiveness research 
using real-world data. For organizational stakehold-
ers, who are likely to weigh the potential value of 
proposed research against both the costs and the 
potential risks, additional research to determine the 
actual costs of data sharing using different methods, 
as well as further evidence regarding the comparabil-
ity of the findings obtained, may help these stake-
holders as they consider the trade-offs associated 
with each method.
A major strength of the study is the inclusion of a 
group of stakeholders with diverse backgrounds, who 
may be involved in multicenter studies. Their participa-
tion in these interviews offered a more comprehensive 
view on the complex issues around data sharing in mul-
ticenter studies. However, our findings should be inter-
preted in the context of the following limitations. This 
was a qualitative study with a relatively selected group 
of stakeholders; while participants brought different 
perspectives, we do not know the extent to which their 
views are representative. We conducted both group and 
individual interviews, which may have influenced our 
findings. The study was not designed to provide gener-
alizable findings. Patients were selected because of their 
engagement with research; their views may not be rep-
resentative of naive patients. On the other hand, their 
feedback may be relevant to PCORnet, which includes a 
network of patients who are actively engaged in research 
activities. Finally, our focus was on sharing information 
currently available in electronic healthcare databases, 
such as diagnoses, pharmaceutical or surgical treatments, 
healthcare encounters and laboratory test results. We did 
not explore issues related to sharing genetic or genomic 
data, and so cannot comment on whether stakeholders’ 
views on that topic would be similar or different.
Conclusion
In this study, we found that stakeholders are open 
to data sharing in multicenter studies if the research 
offers benefits and value to patient care, minimizes 
data security risks, and can be done at reasonable 
cost. The gains in privacy protection associated with 
the use of privacy-protecting analytic and data-shar-
ing methods in multicenter studies were attractive to 
some stakeholders, but others were concerned about 
increased cost and potential loss of research validity 
when using these methods. Most stakeholders were 
not familiar with these newer methods and their 
validity, highlighting the need for better education 
and more research into these methods.
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